Gilead Sciences, Inc.
GILD
$148.95
$5.183.60%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.69% | 2.97% | 1.84% | -0.28% | 6.40% |
| Total Other Revenue | -- | -- | 0.00% | -- | -- |
| Total Revenue | 4.70% | 2.97% | 1.84% | -0.28% | 6.40% |
| Cost of Revenue | 2.47% | -0.32% | -2.78% | -0.77% | 1.35% |
| Gross Profit | 5.29% | 3.84% | 3.16% | -0.14% | 7.81% |
| SG&A Expenses | -4.51% | -4.11% | -0.80% | -10.28% | 17.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.80% | -2.61% | 1.13% | -6.46% | 10.08% |
| Operating Income | 17.77% | 10.64% | 2.97% | 11.47% | -0.32% |
| Income Before Tax | -4.15% | 280.86% | 18.32% | 136.77% | 31.08% |
| Income Tax Expenses | -127.27% | 298.32% | 6.85% | 206.03% | 62.45% |
| Earnings from Continuing Operations | 22.43% | 143.58% | 21.44% | 131.53% | 25.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.43% | 143.58% | 21.44% | 131.53% | 24.77% |
| EBIT | 17.77% | 10.64% | 2.97% | 11.47% | -0.32% |
| EBITDA | 13.75% | 8.64% | 2.27% | 9.02% | -0.09% |
| EPS Basic | 23.02% | 144.36% | 21.63% | 131.56% | 24.78% |
| Normalized Basic EPS | 19.44% | 12.38% | 3.86% | 11.49% | -1.59% |
| EPS Diluted | 23.26% | 143.00% | 20.93% | 131.10% | 24.99% |
| Normalized Diluted EPS | 19.43% | 12.03% | 3.36% | 10.34% | -1.83% |
| Average Basic Shares Outstanding | -0.48% | -0.32% | -0.16% | -0.08% | 0.00% |
| Average Diluted Shares Outstanding | -0.48% | 0.00% | 0.32% | 0.96% | 0.24% |
| Dividend Per Share | -- | 2.60% | 2.60% | 2.60% | 2.67% |
| Payout Ratio | -0.17% | -0.58% | -0.16% | 4.24% | -0.17% |